Myriad Genetics, Inc [NASDAQ: MYGN] price surged by 2.92 percent to reach at $0.21.
The one-year MYGN stock forecast points to a potential upside of 50.07. The average equity rating for MYGN stock is currently 2.65, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Myriad Genetics, Inc [MYGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYGN shares is $14.84 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYGN stock is a recommendation set at 2.65. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Myriad Genetics, Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 09, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $11.50 to $12.50. The new note on the price target was released on March 12, 2025, representing the official price target for Myriad Genetics, Inc stock. Previously, the target price had yet another raise to $29, while Craig Hallum analysts kept a Buy rating on MYGN stock.
The Average True Range (ATR) for Myriad Genetics, Inc is set at 0.49, with the Price to Sales ratio for MYGN stock in the period of the last 12 months amounting to 0.82. The Price to Book ratio for the last quarter was 0.96, with the Price to Cash per share for the same quarter was set at 1.20.
MYGN Stock Performance Analysis:
Myriad Genetics, Inc [MYGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.65. With this latest performance, MYGN shares dropped by -16.46% in over the last four-week period, additionally sinking by -65.63% over the last 6 months – not to mention a drop of -59.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYGN stock in for the last two-week period is set at 33.48, with the RSI for the last a single of trading hit 36.62, and the three-weeks RSI is set at 32.80 for Myriad Genetics, Inc [MYGN]. The present Moving Average for the last 50 days of trading for this stock 9.51, while it was recorded at 7.38 for the last single week of trading, and 17.86 for the last 200 days.
Insight into Myriad Genetics, Inc Fundamentals:
Myriad Genetics, Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.65 and a Current Ratio set at 1.82.
MYGN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MYGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Myriad Genetics, Inc go to 42.36%.
Myriad Genetics, Inc [MYGN] Institutonal Ownership Details
There are presently around $102.48%, or 104.49%% of MYGN stock, in the hands of institutional investors. The top three institutional holders of MYGN stocks are: BLACKROCK INC. with ownership of 15.15 million shares, which is approximately 16.7227%. VANGUARD GROUP INC, holding 10.06 million shares of the stock with an approximate value of $$246.18 million in MYGN stocks shares; and VANGUARD GROUP INC, currently with $$202.1 million in MYGN stock with ownership which is approximately 9.1197%.
